Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin Corporation (NASDAQ:AMRN) presented new analyses of VASCEPA® (icosapent ethyl) at ESC Congress 2021, revealing it reduces major adverse cardiovascular events in patients with prior myocardial infarction (MI) by 26% and total primary endpoints by 35%. Conducted as part of the REDUCE-IT study, these findings highlight VASCEPA's importance in cardiovascular risk management. Experts emphasize its efficacy in patients at high risk for recurrent events, further supporting its role as a treatment beyond statins.
Amarin Corporation has announced that new data supporting the efficacy of VASCEPA in preventing major adverse cardiovascular events will be presented at the ESC Congress 2021, taking place from August 27 to August 30, 2021. The presentations will include two Late-Breaking Science sessions and five e-Posters, showcasing research on icosapent ethyl. CEO Karim Mikhail highlighted the upcoming European launch of VASCEPA, starting in Germany, and anticipates results from the PREPARE-IT 1 trial, which investigates VASCEPA's role in COVID-19 prevention.
Amarin Corporation (NASDAQ:AMRN) reported a net revenue of $154.5 million for Q2 2021, marking a 14% increase from the previous year. The company is set to launch its cardiovascular drug VAZKEPA in Germany by September 2021, having filed market access dossiers in multiple European countries with a proposed pricing of approximately €200 per month. Amarin has received marketing authorization in Great Britain and aims for regulatory approval in 20 additional countries. The company ended Q2 with $523.1 million in cash and investments, enhancing its capacity for growth.
Amarin Corporation plc (NASDAQ:AMRN) announced a conference call to discuss its Q2 and H1 2021 financial results on August 5, 2021, at 7:30 a.m. ET. The call will be available on their investor relations website and via telephone. Investors are encouraged to follow the updates on their website for material information concerning Amarin's ongoing developments in cardiovascular disease management.
Amarin Corporation plc (NASDAQ: AMRN) presented new research on icosapent ethyl, marketed as VASCEPA® and VAZKEPA in Europe, at the EAS Congress 2021. The studies reveal multiple mechanisms by which icosapent ethyl impacts cardiovascular health, including its anti-inflammatory properties and protein modulation. Key findings include the modulation of over 50 proteins in endothelial cells after interleukin-6 exposure, reduction of platelet activation proteins, and decreased nitrite production in macrophages. These insights support icosapent ethyl's role in cardiovascular risk reduction.
Amarin Corporation plc (NASDAQ:AMRN) announced upcoming presentations by CEO John F. Thero and Senior VP Karim Mikhail at two key investor conferences in June 2021. The Jefferies Virtual Healthcare Conference will take place on June 2 at 9:30 a.m. ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 10:30 a.m. ET. Live webcasts will be available on Amarin's website for 30 days. Amarin is committed to advancing cardiovascular disease management through innovative research and clinical trials.
Amarin Corporation announced substantial findings regarding VASCEPA® (icosapent ethyl) from the ACC.21 conference. The REDUCE-IT trial showed a 55% reduction in total plaque volume and a 61% reduction in non-calcified plaque volume, indicating significant cardiovascular risk reduction. Analyses confirmed that icosapent ethyl significantly cut ischemic events by 30-40% in dyslipidemic patients. This data emphasizes the efficacy of icosapent ethyl in managing cardiovascular risk, reinforcing its status as the only approved therapy for this purpose in the U.S., Canada, and Europe.
Amarin Corporation presented new analyses from the REDUCE-IT HEART FAILURE study at ACC.21, highlighting a potential correlation between on-treatment serum EPA levels and reduced incidences of new heart failure and related hospitalizations. The analyses, led by Dr. Deepak L. Bhatt, showed that achieving EPA levels above 150 µg/mL could be beneficial. Despite the overall trial not demonstrating significance for heart failure rates, these findings suggest further exploration is warranted. The study involved 8,179 patients, emphasizing the urgent need to address heart failure, projected to affect over 8 million in the U.S. by 2030.
Amarin Corporation plc (NASDAQ:AMRN) announced that research on VASCEPA® (icosapent ethyl) will be featured in seven presentations at the ACC.21, the American College of Cardiology’s 70th Annual Scientific Session from May 15-17, 2021. Key studies include insights from the REDUCE-IT HF trial and findings on the effects of icosapent ethyl on cardiovascular health. This research aims to address the significant cardiovascular disease burden and is presented by various academic collaborators, emphasizing Amarin's commitment to advancing cardiovascular treatment.
Amarin Corporation reported Q1 2021 revenue of $142.2 million, a 3% decline from Q1 2020 due to COVID-19, severe weather, and increasing generic competition for VASCEPA. Operating expenses decreased by $29 million, leading to a net loss of $1.6 million, an improvement from $20.6 million in Q1 2020. The company received European marketing authorization for VAZKEPA, with a launch planned in Germany by Q3 2021. Amarin ended Q1 with $538.7 million in cash and no debt, emphasizing plans to expand VAZKEPA’s market reach amid ongoing generic competition and COVID-related challenges.
FAQ
What is the current stock price of Amarin (AMRN)?
What is the market cap of Amarin (AMRN)?
